EAU 2026 – J&J strengthens its bladder hand
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
J&J receives Tecvayli/Darzalex nod
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
Regeneron bets big on Lynozyfic
The company is starting four new pivotal trials this year.
M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
ImmunityBio tries again in papillary bladder cancer
And the company says it won’t need to carry out another trial.
J&J claims another second-line Tecvayli win
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
